首页 » BA/F3_EGFR L858R-T790M-C797S激酶Kinase稳定表达细胞株-BioVector NTCC保藏中心

BA/F3_EGFR L858R-T790M-C797S激酶Kinase稳定表达细胞株-BioVector NTCC保藏中心

  • 价  格:¥0
  • 货  号:BA/F3_EGFR L858R-T790M-C797S
  • 产  地:北京
点击询问我要采购
 竭诚为您服务!
BioVector NTCC典型培养物保藏中心
联系人:Dr.Xu, Biovector NTCC Inc.

电话:400-800-2947 工作QQ:1843439339 (微信同号)

邮件:Biovector@163.com

手机:18901268599

地址:北京

已注册
 
BA/F3_EGFR L858R-T790M-C797S激酶Kinase稳定表达细胞株-BioVector NTCC保藏中心
I. Introduction
Cell Line Name:

Ba/F3_EGFR-L858R/T790M/C797S

Gene Synonyms:

Epidermal Growth Factor Receptor, ERBB1, EGFR

Host Cell:

Ba/F3

Stability: 16 passages
Application:

Anti-proliferation assay and PD assay

Freeze Medium:

90% FBS+10% DMSO

Complete Culture Medium:

RPMI-1640+10% FBS+1 ug/ml puromycin

Mycoplasma Status:

Negative


II.Background
EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section). In ligand-activated cancers, Cetuximab appears to be more effective than tyrosine-kinase inhibitors.


III. Representative Data
1. WB of EGFR-L858R/T790M/C797S expression


Figure 1. WB of EGFR Expression
Lane 1: Negative control
Lane 2: EGFR-WT
Lane 3: EGFR-L858R/T790M
Lane 4: EGFR-L858R/T790M/C797S

2. Sanger sequencing


Figure 2. Sanger Sequencing of EGFR-L858R/T790M/C797S

3. Anti-proliferation assay



Figure 3. Anti-proliferation assay of three reference compounds on the Ba/F3_EGFR-L858R/T790M/C797S Stable Cell Line


IV. Thawing

Thawing: Protocol
1. Remove the vial from liquid nitrogen tank and thaw cells quickly in a 37°C water-bath.
2. Just before the cells are completely thawed, decontaminate the outside of the vial with 70% ethanol and transfer the cells to a 15 ml centrifuge tube containing 9 ml of complete growth medium.
3. Pellet cells by centrifugation at 200 x g force for 5 min, and discard the medium.
4. Resuspend the cells in complete growth medium.
5. Add 10 ml of the cell suspension in a 10 cm dish.
6. Add promycin to a concentration of 1 μg/ml the following day.
Kinase细胞株



现代新药研发的关键首先是寻找,确定和制备药物作用靶点。在500多个已发现的药物靶点里中,GPCR,Ion Channel,Kinase使用的最为广泛。




激酶(kinase)是一类从高能供体分子(如ATP)转移磷酸基团到特定靶分子(底物)的酶;这一过程谓之磷酸化。许多肿瘤的发生是由某些与生长相关的“激酶”发生突变导致异常活化引起的,因而针对这些突变激酶的抑制剂能够有效抑制这些激酶的活性,从而达到抑制癌细胞增长的目的。
BioVector NTCC质粒载体菌种细胞蛋白抗体基因保藏中心

电话:+86-010-53513060

网址:www.biovector.net

您正在向 biovector.net  发送关于产品 BA/F3_EGFR L858R-T790M-C797S激酶Kinase稳定表达细胞株-BioVector NTCC保藏中心 的询问

点击“立即发送”后,我们将在1个工作日内与您取得联系。